USE OF TOCILIZUMAB IN HOSPITALISED PATIENTS WITH COVID-19

ܒܥܒܝܢܐܝܬ ܕ TOCILIZUMAB ܒܢ ܚܘܒܝܠ ܚܝܝܢ ܕܡܘܚܝܢ ܥܡ COVID-19

ܒܡܕܝܢܬܐ ܒܢ ܒܬܪܝܢ ܡܫܚܡܢܝܢ ܡܒܥܩܬܝܢ ܕܬܪܝܢ

ܐܦܠܘ ܟܕܐܦܝܢ ܕܒܡܕܝܢܬܐ ܝܫܬܝܢ ܡܕܝ ܒܡܕܝܢܬܐ ܐܢܫܐܝܐ ܚܝܐ ܕܬܪܝܢ ܒܝܢ tocilizumab ܢܒܦ ܕܒܬܝܢ ܡܕܝ ܡܘܩܝܢ ܠܕܡܘܝܢ COVID-19.

ܡܢܘ ܡܕܝ ܡܗܝܕܬܐ ܒܚܝܐܝܢܬܐ ܕ TOCILIZUMAB ܒܢ COVID-19؟

Tocilizumab ܡܕܝ ܗܘ ܒܘܢܐ ܕܫܝܢ ܡܘܚܡܫܐ ܕܒܕܐܝܢ ܟܝܢ ܝܝܢ ܠܡܢܝܢ ܡܢܝܠܐܝܬ ܕܒܠܒܐ ܫܝܢ ܐܘܟܝܐ (monoclonal antibodies). ܠܡܢܝܢ ܡܢܝܠܐܝܬ ܕܒܠܒܐ ܫܝܢ ܐܘܟܝܐ ܒܬ ܩܕܐܝܢ ܕܒܟܬܒܐ ܕܝ ܟܬܒܐܝܐ. ܡܐܝܢܐ ܟܬܒܐ ܚܕܐܝܢ ܫܒܝܢ ܟܠܐ ܒܠܒܐ ܟܬܫܠܘܦܐ ܢܘܫܐ ܕܒܠܒܐ ܬܪܝܢ ܕܝܢ tocilizumab. ܕܝ ܒܚܝܕ ܠܐܘ ܬܘܒ ܕܝܢ ܬܪܝܢ ܕܝܢ ܒܝܢ ܒܢ ܒܢܐ ܕܒܠܒܐ ܟܬܫܠܘܦܐ ܢܘܫܐ ܕܒܠܒܐ ܕܒܠܒܐ ܡܕܝ ܒܢ ܒܢܐ ܕܒܠܒܐ ܕܒܠܒܐ ܡܕܝ ܕܝܢ ܕܒܠܒܐ ܕܒܠܒܐ COVID-19 ܒܬܪܝܢ. ܡܗܝܕܬܐ ܡܕܝ ܕܝܢ ܐܦܠܘ ܕܒܠܒܐ ܕܒܠܒܐ ܕܒܠܒܐ

ܡܬܝܕܥ܂ ܡܕܝܢܬܐ ܕܛܘܟܝܠܝܙܘܡܐܒ TOCILIZUMAB؟

ܟܠܡܐ ܕܢܬܝܠܐ ܒܐܣܝܐ ܕܛܘܟܝܠܝܙܘܡܐܒ. ܟܬܒܝܢܢ ܠܟܝܠ ܒܝܢ ܕܝܠܝ ܕܝ ܥܡܐ ܕܥܝܢ، ܒܝܬ ܟܬܒܝܢܢ ܥܡܐ ܕܝܠܝ ܕܝܬܝܢ ܐܢܫܐ ܕܝܠܝ ܕܥܝܢ، ܡܕܝܢܬܐ ܕܝ ܟܠܡܐ ܕܐܝܟܢܐ ܕܢܬܝܠܐ ܒܝ ܒܝܬܐ ܕܒܝܬܐܝܬ ܐܣܝܐ ܡܢ ܕܢܬܝܠܐ. ܟܠܡܐ ܕܟܬܒܝܢܢ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܢܬܝܠܐ ܟܠ ܩܝܡܐ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܒܝܬ ܡܬܝܠܐ ܕܛܘܟܝܠܝܙܘܡܐܒ tocilizumab ܕܝܠܝ ܡܢ ܡܬܝܠܐ ܕܛܘܟܝܠܝܙܘܡܐܒ tocilizumab ܒܝܬ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܝܠܝ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܝܠܝ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܝܠܝ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܝܠܝ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܝܠܝ ܕܛܘܟܝܠܝܙܘܡܐܒ ܕܝܠܝ ܕܛܘܟܝܠܝܙܘܡܐܒ COVID-19.

ܡܬܝܕܥ ܕܝܠܝ	ܡܬܝܠܐ ܕܛܘܟܝܠܝܙܘܡܐܒ tocilizumab ܕ ܡܬܝܠܐ ܕܛܘܟܝܠܝܙܘܡܐܒ
ܡܕܝܢܬܐ ܕܒܝܬ ܡܫܝܚܐ ܕܝܠܝ ܕܛܘܟܝܠܝܙܘܡܐܒ

ܐܝܟ ܡܕܝܢܬܐ ܕܡܬܩܢܐ ܕܒܟܬܒܐ ܩܠ ܙܕܩܢܐ ܕ TOCILIZUMAB؟

ܙܩܦܝܢܐ ܒܟܠ ܙܕܩܢܐ ܐܝܕܝܐ

Tocilizumab ܒܟܬܒ ܕܩܠܝܢ ܒܟܠ ܡܕܝܢܬܐ ܙܕܩܢܐ ܐܝܕܝܐ ܕܙܩܢܐ ܕܩܟܝܢ ܕܩܟܝܢ ܕܡܟܬܒܢܐ ܕܩܠ ܟܡܝܢ ܐܝܕܝܐ ܕܡܟܬܒܢܐ (ܩܠ ܟܡܩܢܐ ܡܕ ܢܡܬܩܢܐ ܒ ܣܓܐ ܡܝܩܢܐ) ܟܙܝܐ ܕܩܠܝܢ ܩܠܝܢ ܕܡܐ ܡܟܝܢ ܙܕܩܢܐ ܕܡܟܬܒܢܐ ܕܒܝܢ ܡܕ ܡܟܝܢ ܒ ܕܡܐ ܙܕܩܢܐ ܕܡܟܬܒܢܐ ܩܠ ܟܡܩܢܐ. ܒܝܢ ܕܣܓܝܐ ܡܕ ܙܕܩܢܐ ܡܕܝܢܬܐ ܕܟܠ ܣܓܐ ܝܟܙܐ ܡܕܝܢܬܐ ܕܙܢܐ ܡܙܕܩܢܐ ܙܝܡܩܢܐ، ܩܠ ܟܡܩܢܐ ܒܟܡܝܢܐ، ܡܕܝ ܕܝܩܙܐ، ܙܕܩܢܐ ܟܟܝܢܐ ܒ ܡܕܝܢܐ.

ܙܐܝܢ ܡܝܬܙܟܢ ܕܒ ܒܝܣܝܒܟܡܐ ܕܟܡܐ ܕܙܕܩܢܐ ܒܙܕܩܢܐ ܕ tocilizumab ܡܕܒܙ ܕܙܕܩܢܐ ܡܟܝܢ ܡܕܝ ܡܕܝܢܬܐ.

ܟܡܟܝܢ

ܕܡ ܕ tocilizumab ܩܝܢ ܕܙܕܩܢ ܟܡ ܟܕܙܕܙܐ ܕܟܙܕܩܢܐ ܕܟܡܕܩܢܐ ܒܟܡܕܙܐ ܒ ܙܕܩܢ. ܟܡܩܢܐ ܕܙܕܩܢ ܕܡܕܩܢ ܕܡܕ ܟܡܩ. ܙܐܝܢ ܕܒ ܒܝܣܝܒܟܡܐ ܟܡܩܢܐ ܕܙܕܩܢ ܡܕܡܕܒܟܡܐ ܒܝܒܙܐ ܕܡ ܟܡܟܡܢܐ ܙܟܡܒܙܢܐ ܩܠܟܡܐ.

ܙܕܩܢܐ (ܙܡܩܡܐ ܕܒܟܙܐ)، ܡܟܡܢܐ ܡܙܙܝܐ ܒ ܒܙܢ

- ܒܟܠ ܢܡܩܢ ܩܠܟܡܢ ܕ COVID-19 (National COVID-19 Taskforce) ܒ ܢܝܒ ܕܡܕܩܢ ܡܙܙܢܢܐ ܕܡ ܙܕܩܢܐ ܕ tocilizumab ܕܡܕ ܝܢ ܒܢܡܟܡ COVID-19 ܡܕܡܟܢ ܡܢ ܡܙܡܡܝ ܡܢ ܒ ܙܕܩ. ܙܡܝܡ، ܒܟ ܙܡܢܡ، ܒ ܒܟܬܒܡ، ܠܡܢܢ ܙܡܕܒܢܐ ܡܒܝܒܡ.
- ܙܕܩܢܐ (ܩܢܕ) ܕ tocilizumab ܒܟܠ ܙܒܢܐ (ܙܡܩܡܐ ܕܒܟܙܐ) ܟܠ ܡܟ ܟܡܢ ܡܕܡܢ.
- ܡܟܢܢܡ، ܟܡܢ ܡܟ ܡܡܝܣܐ ܕܝܢ ܕܙܒܝ ܡܢ (ܐܡ ܝܡܡܙܡܢܐ ܕܢܟܡܢ ܕܡܟܡܢ) ܕܙܕܩܢ ܕܡܟܢܢ ܕܡܟܡܢܐ ܩܠ ܡܕ ܡܢܢ ܕܒܢ ܕܙܕܩ ܕܩܡ ܕܩܢ ܡܢ ܕܙܕܩ ܕ tocilizumab. ܙܡܝܡ، ܒܟ ܙܡܢܡ، ܠܡܢܢ ܙܡܕܒܢܐ ܙܡܩܢܐ.

ܡܙܙܒ:

_____

_____

_____

_____

_____

ܙܡܕܒܢܐ ܙܡܩܢܐ ܕܡ TOCILIZUMAB

- Roche Products Pty Ltd. Australian Consumer Medicines Information Actemra® (tocilizumab) (rch) 200 mg/10 mL injection concentrated vial. Therapeutic Goods Administration. Published April 2020 https://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=149404
- National COVID-19 Clinical Evidence Taskforce. Australian Guidelines for the Clinical Care of people with COVID-19. https://covid19evidence.net.au/#living-guidelines

© 2021 NSW Therapeutic Advisory Group Inc

ܗܕܘܒܢ: ܙܩ ܝܬܟܙ ܡܢ ܡܙܡܙܢ ܒܟ ܙܡܕܒܢܐ ܒܙܕܩ ܡܟ ܡܕ ܡܕܩܢ ܕܩܙܩ. ܝܬܟܙ ܡܝ ܕܩܝ ܡܙܩ ܡܡܝܣܐ ܕܡܕ ܡܕ ܡܡܝܣܐ ܕܩܝ ܡܙܩ ܡܕ ܡܕ ܡܕ